2. Покровский В.В, Ладная Н.Н., Соколова Е.В. ВИЧ-инфекция в Российской Федерации 31 декабря 2022 года. www.hivrussia.info

Pokrovsky V.V., Ladnaia N.N., Sokolova E.V. (HIV infection in the Russian Federation on December 31, 2022.). (In Russ.). www.hivrussia.info

3. Yin Z, Rice BD, Waight P, Miller E., George R., Brown A.E. et al. Invasive pneumococcal disease among HIV-positive individuals. 2012 Jan 2;26(1):87-94. DOI: 10.1097/QAD.0b013e32834dcf27

4. Thio C.L., Seaberg E.C., Skolasky R. Jr., Phair J., Visscher B., Muñoz A. et al. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921–6. DOI: 10.1016/S0140-6736(02)11913-1

5. Драпкина О.М., Брико Н.И., Костинов М.П., Фельдблюм И.В., Алыева М.Х., Андреева Н.П. и др. Иммунизация взрослых. Методические рекомендации. ФГБУ НМИЦ ТПМ Минздрава России. М, 2020. 248 с.

Drapkina O.M., Briko N.I., Kostinov M.P., Feldblum I.V., Alyeva M.Kh., Andreeva N.P. et al. (Immunization of adults. Guidelines). Moscow, 2020. 248 p. (In Russ.).

6. Eramova I., Matic S., Munz M. (eds). HIV/AIDS treatment and care: clinical protocols for the WHO European Region. 2007. http://www. euro.who.int/_data/assets/pdf_file/0004/78106/E90840.pdf

7. World Health Organization. Vaccine position papers. http://www.who.int/ immunization/documents/positionpapers/en/

8. British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015. http://www.bhiva.org/documents/Guidelines/Immunisation/ consultation/BHIVA-Immunisation-Guidelines-2015-Consultation.pdf.

9. ACIP: General Best Practice Guidelines for Immunization: Altered Immunocompetence. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html

10. The European Clinical AIDS Society (EACS) Guidelines for HIV Treatment. Version 8.2. January 2017. http://www.eacsociety.org/ guidelines/eacs-guidelines/eacs-guidelines.html

13. Aberg J.A., Gallant J.E., Ghanem K.G., Emmanuel P., Zingman B.S., Horberg M.A. Recommendations for primary care for people infected with HIV: 2013 update prepared by the Association of HIV Medicine of the American Society of Infectious Diseases. A clinical case of infection. 2014; 58(1): e1–34. DOI:10.1093/cid/cit665

14. Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Буравцова Е.В., Деулина М.О. и др. Рекомендации по лечению ВИЧ-инфекции и связанных с ней заболеваний, химиопрофилактике заражения ВИЧ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2023; 12(4, приложение). 109 с.

Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Buravtsova E.V., Deulina M.O. et al. (Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection). Epidemiology and infectious diseases. Current items 2023; 12(4, application). 109 с. (In Russ.).

15. Abadom T.R., Smith A.D., Tempia S., Madhi S.A., Cohen S., Cohen Dr. Risk factors associated with hospitalization for severe acute respiratory illness associated with influenza in South Africa: a population-based study. Vaccine 2016; 34: 5649–55. DOI: 10.1016/j.vaccine.2016.09.011

16. Cohen S., Moyes J., Tempia S., Groome M., Walaza S., Pretorius M. et al. Mortality among patients with severe acute respiratory illness associated with influenza, South Africa, 2009–2013. PLoS One 2015; 10: e0118884. DOI: 10.1371/journal.pone.0118884

17. Shet A.N., Eltoff K.N., Brooks J.T. Susceptibility to influenza, severity and spread in HIV-infected adults: a literature review. A clinical case of infection. 2011; 52: 219–27. DOI: 10.1093/cid/ciq110

18. Atashili J., Kalilani L., Adimora A.A. Efficacy and clinical manifestations of influenza vaccines in HIV-infected individuals: A meta-analysis. BMC Infect Dis. 2006; 11(6): 138. DOI: 10.1186/1471-2334-6-138

19. Beck C.R., McKenzie B.C., Hashim A.B., Harris R.C. University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group. Nguyen-Van-Tam JS. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis. 2012; 206: 1250–9. DOI: 10.1093/infdis/jis487

20. Nunes M.C., von Gottberg A., de Gouveia L., Cohen C., Moore D.P., Klugman K.P. et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. AIDS 2011; 25: 453–62. DOI: 10.1097/QAD.0b013e328341b7f1

21. McLaughlin J., Jiang Q., Isturiz R.E., Sings H.L., Swerdlow D.L., Gessner B.D. et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin. Infect. Dis. 2018; 67(10): 1498–1506. DOI: 10.1093/cid/ciy312

22. Sadlier C., O’Dea S., Bennett K., Dunne J., Conlon N., Bergin C. Immunological efficacy of pneumococcal vaccine strategies in HIV-infected adults: a randomized clinical trial. Sci. Rep. 2016; (6): 32076. DOI: 10.1038/srep32076

23. Чучалин А.Г., Брико Н.И., Авдеев С.Н., Белевский А.С., Биличенко Т.Н., Демко И.В. и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология 2019; 29(1): 19–34. DOI: 10.18093/0869- 0189-2019-29-1-19-34

Chuchalin A.G., Briko N.I., Avdeev S.N., Belevsky A.S., Bilichenko T.N., Demko I.V. and others. (Federal clinical recommendations for vaccine prevention of pneumococcal infection in adults). Pulmonology 2019; 29 (1): 19–34. (In Russ.). DOI: 10.18093/0869-0189-2019-29-1-19-34

24. Покровский В.В., Ладная Н.Н., Киреев Д.Е., Хохлова О.Н., Серебровская Л.В., Покровская А.В. и др. Лекции по ВИЧ-инфекции. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2018: 396–424.

Pokrovsky V.V., Ladnaya N.N., Kireev D.E., Khokhlova O.N., Serebrovskaya L.V., Pokrovskaya A.V. et al. (Lectures on HIV infection). 2nd ed., reprint. and additional. Moscow: GEOTAR-Media, 2018: 396–424. (In Russ.).

25. Li Wu., Wang X., Li T. Coinfection with hepatitis B virus/human immunodeficiency virus: the interaction between infection caused by human immunodeficiency virus, chronic infection caused by hepatitis B virus, and host immunity. Chin. Med. J. 2012; 125(13): 2371–7. DOI: 10.3760/cma.j.issn.0366-6999.2012.13.023

26. Landrum M.L., Huppler Hullsiek K., Ganesan A. Hepatitis B vaccine responses in a large US military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4+ count. Vaccine 2009; 27: 4731–8. DOI: 10.1016/j.vaccine.2009.04.016.

27. Bailey C.L., Smith V., Sands M. Hepatitis B vaccine: a seven-year study of adherence to the immunization guidelines and efficacy in HIV-1-positive adults. Int. J. Infect. Dis. 2008; 12: e77–e83. DOI: 10.1016/j.ijid.2008.05.1226.

28. Launay O., Grabar S., Gordien E, HEPAVAC Study Group et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J. Acquir. Immune Defic. Syndr. 2008; 49: 272–5. DOI: 10.1097/QAI.0b013e318183a9c0

29. Mena G., García-Basteiro A.L., Llupià A, Díez C., Costa J., Gatell J.M. et al. Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. Vaccine 2013; 31: 3668–74. DOI: 10.1016/j.vaccine.2013.06.012

30. Kourkounti S., Papaizos V., Leuow K., Kordosis T., Antoniou C. Hepatitis A vaccination and immunological parameters in HIV-infected patients. Viral Immunol. 2013; 26: 357–63. DOI: 10.1089/vim.2012.0100

31. Jabłonowska E., Kuydowicz J. Durability of response to vaccination against viral hepatitis A in HIV-infected patients: a 5-year observation. Int. J. STD AIDS 2014; 25: 745–50. DOI: 10.1177/0956462413518902

32. Wallace M.R., Brandt C.J., Earhart K.C., Kuter B.J., Grosso A.D., Lakkis H. et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin. Infect .Dis. 2004; 39: 1207–13. DOI: 10.1086/424666

33. Miller L., Arakaki L., Ramautar A., Bodach S., Braunstein S.L., Kennedy J. et al. Increased risk of invasive meningococcal infection among people with HIV. Ann. Intern. Med. 2014; 160: 30–7. DOI: 10.7326/P14-9011.

34. Meiring S, Cohen C., Gouveia L., Plessis M., Ganesh K., Kleynhans J. et al. Human immunodeficiency virus infection is associated with increased meningococcal carriage acquisition among first-year students in 2 South African Universities. Clin. Infect. Dis. 2021; 73(1): e28–e38. DOI:10.1093/cid/ciaa521

35. Borrow R., Alarcón P., Carlos J., Caugant D.A. et al. The Global Meningococcal Initiative: global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection. Expert Rev. Vaccines 2017; 16(4): 313–28. DOI: 10.1080/14760584.2017.1258308

36. Снегирева И.И., Глаголев С.В., Поливанов В.А., Косенко В.В., Пархоменко Д.В., Мельникова А.А. и др. Методические рекомендации по выявлению, расследованию и профилактике побочных проявлений после иммунизации. (Утв. Минздравом России 12.04.2019)

Snegireva I.I., Glagolev S.V., Polivanov V.A., Kosenko V.V., Parkhomenko D.V., Melnikova A.A., et al. (Methodological recommendations for identifying, investigating and preventing adverse events after immunization). (Approved by the Ministry of Health of Russia on April 12, 2019). (In Russ.).

37. Bertolini D.V., Costa L.S., van der Heijden I.M., Sato H.K., Marques H.H. Immunogenicity of meningococcal conjugate serogroup C vaccine in HIV-infected children, adolescents and young adults. Vaccine 2012; 30: 5482–86. DOI: 10.1016/j.vaccine.2012.06.069

38. Bonetti T.C., Succi R..C, Weckx L.Y.., Tavares-Lopes L., de Moraes-Pinto M.I. Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004; 22: 3707–12. DOI: 10.1016/j.vaccine. 2004.03.023

39. Krohn F.P., van Diess J.T., Labadi J., van Loon A.M., van Firth R. Antibody response to vaccines against diphtheria, tetanus and polio depending on the number of CD4+ T-lymphocytes in adults infected with human immunodeficiency virus. Clin. Infect. 1995; 21: 1197–203. DOI: 10.1093/clinids/21.5.1197

40. Rosenblatt H.M., Song L.Y., Nachman S.A., Pediatric AIDS Clinical Trials Group 377 Study Team et al. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J. Allergy Clin. Immunol. 2005; 116: 698–703. DOI: 10.1016/j.jaci.2005.05.016

41. Chaturvedi A.K., Madeleine M.M., Biggar R.J., Engels E.A. Risk of human papillomavirus-associated cancers among persons with AIDS. J. Nat. Cancer Inst. 2009; 101: 1120–30. DOI: 10.1093/jnci/djp205

42. Silverberg M.J., Lau B., Justice A.C. North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin. Infect. Dis. 2012; 54: 1026–34. DOI: 10.1093/cid/cir1012

43. Giacomet V., Penagini F., Trabattoni D., Viganò A., Rainone V., Bernazzani G. et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014; 32: 5657–61. DOI: 10.1016/j.vaccine.2014.08.011

44. Kojic E.M., Kang M., Cespedes M.S., Umbleja T., Godfrey C., Allen R.T. et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin. Infect. Dis. 2014; 59: 127–35. DOI: 10.1093/cid/ciu238

45. Gebo K.A., Kalyani R., Moore R., Polydefkis M.J. Frequency, risk factors and consequences of herpes zoster among HIV-infected people in the era of highly active antiretroviral therapy. J. Acquir. Immune Deficiency Syndr. 2005; 40: 169–74.

46. Anderson T.C., Masters N.B., Guo A., Shepersky L., Leidner A.J., Lee G.M. et al. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥ 19 Years: Recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR 2022; 71(3): 80–4. DOI: 10.15585/mmwr.mm7103a2

47. Pan C.X., Lee M.S., Nambudiri V.E. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Therapeutic Advances in Vaccines and Immunotherapy 2022; 10(9): 251513552210845. DOI: 10.1177/25151355221084535

48. Мовсесянц А.А., Олефир Ю.В. Современные проблемы вакцинопрофилактики бешенства. БИОпрепараты. Профилактика, диагностика, лечение 2019; 19(1): 10–6. https://doi.org/10.30895/2221-996X-2019-19-1-10-16

Movsesyants A.A., Olefir Yu.V. (Modern problems of rabies vaccine prevention). BIOpreparations. Prevention, diagnosis, treatment 2019; 19(1): 10–6. (In Russ.). https://doi.org/10.30895/2221-996X-2019-19-1-10-16

49. WHO Expert Consultation on Rabies, third report: WHO Technical Series Report. Geneva, 2018. https://apps.who.int/iris/handle/10665/272364

50. Kaplan L.J., Daum R.S., Smaron M., McCarthy K.A. Severe measles in immunocompromised patients. JAMA 1992; 267: 1237–41.

51. Wallace M., Hooper D.G., Graves S.J., Malone J.L. Measles seroprevalence and vaccination response in HIV-infected adults. Vaccine 1994; 12: 1222–4.

52. Angel J.B., Walpita P., Lurch R.A., Sidhu M.S., Masurekar M., DeLellis R.A et al. Measles pneumonitis associated with the vaccine in an adult with AIDS. Ann. Int. Med. 1998; 129: 104–6.

53. Authors are not specified. Measles pneumonitis after vaccination of a patient with HIV infection against measles, mumps and rubella, 1993. MMWR Morb. Mortal Wkly Rep. 1996; 45: 603–6.

54. Measles vaccines: WHO position paper, April 2017. Recommendations. Vaccine 2019; 37(2): 219–22. https://doi.org/10.1016/j.vaccine.2017.07.066

55. Popara M., Pendle S., Sacks L., Smego R., Mer M. Varicella pneumonia in patients with HIV/AIDS. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2002; (6): 6–8. DOI: 10.1016/s1201-9712(02)90128-1

56. Kramer J.M., Larousse P., Tsai W.C., Carney P., Leber S.M., Gahagan S. et al. Disseminated vaccine strain of chickenpox as a disease determining acquired immunodeficiency syndrome in a previously undiagnosed child. Pediatrics 2001; 108(2): е39. DOI: 10.1542/peds.108.2.e39